Ankylosing Spondylitis Market Introduction and Overview
According to SPER market research, ‘Ankylosing Spondylitis Market Size- By Drug Class, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Ankylosing Spondylitis Market is predicted to reach 11.75 billion by 2034 with a CAGR of 6.66%.
Ankylosing spondylitis (AS) is a chronic inflammatory illness mostly affecting the spine and sacroiliac joints, causing pain, stiffness, and progressive vertebral fusion. It is characterized as axial spondyloarthritis and is often related with the HLA-B27 genetic marker. AS primarily affects young adults, with symptoms beginning in late adolescence or early adulthood. Over time, inflammation can cause vertebrae to fuse, resulting in diminished spinal flexibility and a stooped posture.
Restraints: One of the most significant obstacles is the high expense of biologic medicines such as TNF inhibitors and IL-17 inhibitors, which makes treatment inaccessible for many patients, particularly those in low- and middle-income countries. Furthermore, delayed identification due to the non-specific early symptoms of AS frequently results in disease progression before correct therapy can begin, reducing the efficacy of existing medicines.
Scope of the Report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Drug Class, By Distribution Channel.
Regions covered
North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
Companies Covered
AbbiVie, Inc, Amgen, Inc, Eli Lilly and Company, Izana Biosciences, Johnson and Johnson Services, Inc, Merck and Co., Inc, Novartis AG, Pfizer, Inc, UCB, Inc, Zydus Lifescience Ltd. and others.
Ankylosing Spondylitis Market Segmentation:
By Drug Class: Based on the Drug Class, Global Ankylosing Spondylitis Market is segmented as; Non-Steroidal Anti-Inflammatory Drug (NSAID), TNF Inhibitors.
By Distribution Channel: Based on the Distribution Channel, Global Ankylosing Spondylitis Market is segmented as; Hospital Pharmacy, Retail Pharmacy.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Global Ankylosing Spondylitis Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Ankylosing Spondylitis Market
- 7. Global Ankylosing Spondylitis Market, By Drug Class (USD Million) 2021-2034
- 7.1. Non-Steroidal Anti-inflammatory Drug (NSAID)
- 7.2. TNF inhibitors
- 7.2.1. Humira
- 7.2.2. Simponi
- 7.2.3. Remicade
- 7.2.4. Enbrel
- 7.2.5. Cimzia
- 8. Global Ankylosing Spondylitis Market, By Distribution Channel (USD Million) 2021-2034
- 8.1. Hospital Pharmacy
- 8.2. Retail Pharmacy
- 9. Global Ankylosing Spondylitis Market, (USD Million) 2021-2034
- 9.1. Global Ankylosing Spondylitis Market Size and Market Share
- 10. Global Ankylosing Spondylitis Market, By Region, (USD Million) 2021-2034
- 10.1. Asia-Pacific
- 10.1.1. Australia
- 10.1.2. China
- 10.1.3. India
- 10.1.4. Japan
- 10.1.5. South Korea
- 10.1.6. Rest of Asia-Pacific
- 10.2. Europe
- 10.2.1. France
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. United Kingdom
- 10.2.6. Rest of Europe
- 10.3. Middle East and Africa
- 10.3.1. Kingdom of Saudi Arabia
- 10.3.2. United Arab Emirates
- 10.3.3. Qatar
- 10.3.4. South Africa
- 10.3.5. Egypt
- 10.3.6. Morocco
- 10.3.7. Nigeria
- 10.3.8. Rest of Middle-East and Africa
- 10.4. North America
- 10.4.1. Canada
- 10.4.2. Mexico
- 10.4.3. United States
- 10.5. Latin America
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Rest of Latin America
- 11. Company Profile
- 11.1. AbbiVie, Inc
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
- 11.2. Amgen, Inc
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
- 11.3. Eli Lilly and Company
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
- 11.4. Izana Biosciences
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
- 11.5. Johnson and Johnson Services, Inc
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
- 11.6. Merck and Co., Inc
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
- 11.7. Novartis AG
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
- 11.8. Pfizer, Inc
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
- 11.9. UCB, Inc
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
- 11.10. Zydus Lifescience Ltd
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
- 11.11. Others
- 12. Conclusion
- 13. List of Abbreviations
- 14. Reference Links
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook